Document is current
Any future updates will be listed below
-
Authors
Nasu, Risa https://orcid.org/0000-0002-5258-8593
Oura, Tomonori https://orcid.org/0000-0003-0872-8576
Ohwaki, Kenji https://orcid.org/0000-0002-2842-8231
Imori, Makoto
Furihata, Kenichi
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 15 January 2025
First Online: 10 February 2025
Declarations
:
: Risa Nasu, Tomonori Oura, Kenji Ohwaki, and Makoto Imori are employees of Eli Lilly Japan K.K. and minor stockholders of Eli Lilly and Company. Kenichi Furihata has received consulting fees from Kissei Pharmaceutical.
: The trials were approved by independent ethical review boards at each participating site and were conducted in accordance with the Declaration of Helsinki 1964 and its later amendments. All study participants provided written informed consent. The trials were registered with ClinicalTrials.gov (NCT03603704 and NCT04276428).
